- Home
- CPBI vs DXR Comparison
CPBI vs DXR Comparison
Compare CPBI & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CPBI | DXR |
|---|---|---|
| Founded | 2023 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.5M | 59.0M |
| IPO Year | 2023 | 1995 |
Fundamental Metrics
Financial Performance| Metric | CPBI | DXR |
|---|---|---|
| Price | $19.62 | $10.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.9K | 2.1K |
| Earning Date | 06-12-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.38 | N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | N/A | ★ $1,446,345.00 |
| Revenue This Year | N/A | $44,935.22 |
| Revenue Next Year | N/A | $74.79 |
| P/E Ratio | ★ $19.05 | $33.83 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.85 | $8.56 |
| 52 Week High | $21.83 | $14.76 |
Technical Indicators
Market Signals| Indicator | CPBI | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 64.87 | 48.14 |
| Support Level | $17.03 | $9.64 |
| Resistance Level | N/A | $10.65 |
| Average True Range (ATR) | 0.33 | 0.31 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 30.46 | 37.59 |
Price Performance
Historical ComparisonAbout CPBI Central Plains Bancshares Inc.
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.